Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.

Translated title of the contribution: Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.

L.H. van der Helm, C. Alhan, P.W. Wijermans, M. van Marwijk-Kooy, R. Schaafsma, B.J. Biemond, A. Beeker, M. Hoogendoorn, B.P. van Rees, O. de Weerdt, J. Wegman, W.J. Libourel, S.A. Luykx-de Bakker, M.C. Minnema, R.E. Brouwer, F. Croon-de Boer, M. Eefting, K-S.G. Jie, A.A. van de Loosdrecht, J. KoedamN.G.J.M. Veeger, E. Vellenga, G. Huls

Research output: Contribution to journalArticleAcademicpeer-review

Translated title of the contributionPlatelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
Original languageUndefined/Unknown
Pages (from-to)599-606
Number of pages8
JournalBritish Journal of Haematology
Volume155
Issue number5
Publication statusPublished - 2011

Cite this